Locally Advanced Malignant Neoplasm Clinical Trial
Official title:
Ride to Care - A Pilot Study to Investigate the Clinical and Quality of Life Benefit of Eliminating Transportation Barriers for Disadvantaged Cancer Patients Undergoing Ambulatory Palliative Radiotherapy
Verified date | May 2021 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well Uber health intervention works in eliminating transportation barriers for disadvantaged patients with cancer that has spread to nearby tissue, lymph nodes, or other places in the body, undergoing ambulatory palliative radiotherapy. Uber health intervention provides free transportation to disadvantaged patients and may reduce the amount of missed radiotherapy appointments, patient anxiety, and the amount of unplanned emergency department visits, as well as improve quality of life.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2024 |
Est. primary completion date | February 4, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent (and assent when applicable) obtained from patient or patients's legal representative and ability for patient to comply with the requirements of the study - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Histologically confirmed locally advanced or metastatic cancer - Patients who have received prior courses of radiotherapy are eligible - If patient answers yes to >= 1/4 of the questions below: - In the last six months, have you ever delayed seeing a doctor or getting care? - Do you anticipate having a hard time coming to University of California, San Francisco (UCSF) for radiation therapy due to transportation challenges? - Does lack of money for transportation expenses (parking, taxi, bus) make it difficult for you to get care quickly for medical problems? - Does arranging for transportation (driving yourself, getting neighbor or family to drive you) for your cancer treatments make you anxious or worried?" Exclusion Criteria: - Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data - Patients who are living at a facility such as a nursing home or skilled nursing facility - Patients who do not live within a 30-mile radius of one of the radiation oncology sites at University of California San Francisco (UCSF) - Patients who are currently receiving or expected to be receive UCSF affiliated transportation services prior to enrollment onto the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of unplanned emergency department (ED) visits | For each enrolled patient, any unplanned ED visit over the six months from consultation/enrollment will be documented as an event. | Up to 6 months | |
Primary | Rate of unplanned hospital admissions | For each enrolled patient, any unplanned hospital admission the six months from consultation/enrollment will be documented as an event. | Up to 6 months | |
Secondary | Change in mean pain score on the European Organization for Research and Treatment of Cancer quality of life questionnaire 30 (EORTC-QLQ-C30) | The Pain score consists of responses to two items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the two items that make up the pain scale with a resulting total range of 1-4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the pain scale / item represents a high level of symptomatology / problems. | Up to 3 years | |
Secondary | Change in mean overall global health status score on the EORTC-QLQ-C30 | The global health status score consists of responses to two items with responses ranging from 1="very poor" to 4="excellent". The raw score is calculated by estimating the mean of the two items that make up the global health scale with a resulting total range of 1-7. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the global health status represents a higher quality of life. | Up to 3 years | |
Secondary | Change in functional domain scores on the EORTC-QLQ-C30 | The functional domains measure the quality of life in Physical functioning, Role functioning, Emotional functioning, Cognitive functioning, Social functioning. Scores consists of responses to items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning | Up to 3 years | |
Secondary | Percentage of participants who completed total treatment | Measured by the number of patients who complete treatment in the total sample of participants. | Up to 3 years | |
Secondary | Median days of treatment delays | Will be tabulated. A Mann-Whitney test will be used to compare the two groups. | Up to 3 years | |
Secondary | Number of participants with a reported treatment delay | Will be measured by the ratio of time elapsed to time expected. Patients are assumed to require 2 business days between referral and consult and 3 business days between consult and treatment start. T1/T0, such that time elapsed (T1) = total days between initial referral and treatment completion. Time expected (T0) = 5 + total days of radiation prescribed . | Up to 3 years | |
Secondary | Number of participants with grade >= 3 acute radiation related adverse events | Treatment-related acute adverse events will be classified using the Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 and tabulated. | Up to 3 years | |
Secondary | Number of participants with grade >= 3 chronic radiation related adverse events | Treatment-related chronic adverse events will be classified using the Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 and tabulated. | Up to 3 years | |
Secondary | Percentage of participant requiring re-treatment | Defined as the number of participants who needed to undergo re-irradiation due to recurrence or progression at the treatment site in the total sample. | Up to 3 years | |
Secondary | Overall survival (OS) | Participants will be followed from enrollment until end of study or death, whichever occurs first. OS will be assessed using Cox-proportional Hazard models | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03671226 -
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
|
N/A | |
Completed |
NCT01973673 -
Healthy Bones Study
|
N/A | |
Completed |
NCT01876927 -
Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer
|
Phase 2 | |
Terminated |
NCT03295942 -
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
|
Phase 1 | |
Completed |
NCT03238027 -
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02823652 -
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
|
N/A | |
Completed |
NCT02227082 -
Olaparib and Radiotherapy in Inoperable Breast Cancer
|
Phase 1 | |
Recruiting |
NCT01871363 -
Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer
|
Phase 2 | |
Completed |
NCT01847001 -
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT03170115 -
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT04749108 -
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
|
Phase 2/Phase 3 | |
Terminated |
NCT01836432 -
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT01675999 -
Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
|
Phase 2 | |
Completed |
NCT01333709 -
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
|
Phase 2 | |
Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03856060 -
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
|
N/A | |
Completed |
NCT04186884 -
Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
|
||
Recruiting |
NCT04112836 -
Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
|
||
Not yet recruiting |
NCT03051152 -
D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma
|
N/A |